Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment (Q37269617)

19 August 2017

Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

1 reference

1

Laura J Havrilesky

1 reference

19 August 2017

2

Gloria Broadwater

1 reference

19 August 2017

Debra M Davis

3

1 reference

19 August 2017

Kimberly C Nolte

4

1 reference

19 August 2017

J Cory Barnett

5

1 reference

19 August 2017

Evan R Myers

6

1 reference

19 August 2017

Shalini Kulasingam

7

1 reference

19 August 2017

language of work or name

English

0 references

publication date

12 February 2009

1 reference

19 August 2017

1 reference

19 August 2017

113

1 reference

19 August 2017

2

1 reference

19 August 2017

216-220

1 reference

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Putting the 'Q' in quality adjusted life years (QALYs) for advanced ovarian cancer - An approach using data clustering methods and the internet

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

New tumor markers: CA125 and beyond.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Serum protein markers for early detection of ovarian cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

A review of the use of health status measures in economic evaluation.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Treatment preferences in recurrent ovarian cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713675

A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.026

Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists

7 January 2021

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.026

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial

7 January 2021

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.026

10.1016/J.YGYNO.2008.12.026

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19217148

1 reference